As it stands, Epitalons pharmacological profile is promising but incomplete, raising key questions about long-term safety, optimal dosing, and how to harness its effects in a reliable, standardized way
That last qualifier matters: an open-label study with exploratory endpoints generates encouraging signals and answers a specific dosing question, but it cannot substitute for the randomized, controlled cirrhosis-outcome trial now underway in Phase 3
Specific POPs have been associated with a higher risk for peripheral neuropathy among those with either impaired fasting glucose or diabetes, beyond the heightened risk due to diabetes itself
When paired with high-dose Vitamin C, which boosts glutathiones effectiveness, the results are even more noticeable and long-lasting
Regulatory Status Notice: BPC-157 exists within a complex and evolving regulatory environment